Stocktoria
Intellia Therapeutics, Inc. NTLA
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2016-05-06
Intellia Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% |
| Net margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% |
| FCF margin | -585.0% | -612.8% | -1124.9% | -665.5% | -719.4% |
| Return on assets | -49.0% | -43.6% | -37.0% | -31.2% | -20.7% |
| Return on equity | -61.5% | -59.5% | -45.8% | -38.4% | -25.8% |
| Current ratio | 5.08 | 5.77 | 8.67 | 9.61 | 6.11 |
| Revenue growth | 16.9% | 59.6% | -30.4% | 57.7% | -43.0% |
Source: SEC EDGAR filings · CIK 0001652130 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.